Connect to other sites within the UBM Medica Network
Alectinib Shows Response in Crizotinib-Refractory NSCLC
The ALK inhibitor alectinib was highly active and well-tolerated in patients with ALK-rearranged, crizotinib-refractory, advanced non–small-cell lung cancer.
Nintedanib Delays Progression of Advanced Ovarian Cancer
Women with chemotherapy-naive advanced ovarian cancer gained significant delays in the progression of their disease when adding nintedanib to carboplatin/paclitaxel.
November 2015 News Roundup
In this news roundup for November 2015 we highlight some of the top stories of the month, including several FDA approvals, new breast cancer guidelines, and more.
FDA Approves Necitumumab (Portrazza) for Advanced Squamous NSCLC
The FDA has approved necitumumab (Portrazza) in combination with chemotherapy for the treatment of patients with metastatic squamous non-small-cell lung cancer.
NYC Program Diminishes Disparities, Sees Uptick in CRC Screening
A program implemented in New York City successfully increased colorectal cancer screening rates and diminished racial and ethnic disparities in screening.
Innovative GBM Trial Could Hasten Development of New Treatments
Innovative “adaptive” clinical trial designs are using molecular tools and biomarkers in ways that will streamline research efforts and bring new treatments more quickly to regulatory approval and clinical use.
Frontline Nivolumab Approved for BRAF Wild-type Melanoma
Today the FDA approved the PD-1 inhibitor nivolumab (Opdivo) as a single-agent frontline treatment for patients with BRAF wild-type advanced melanoma.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
Adjuvant Chemo Ups Survival in High-Risk Localized Prostate Cancer
The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
By clicking Accept, you agree to become a member of the UBM Medica Community.